/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITES STATES/
MONTREAL, Nov. 6 /CNW Telbec/ - OPMEDIC GROUP Inc. ("OPMEDIC GROUP")
(TSX: "OMG"), through its division Procrea Cliniques, in its pursuit to
provide innovative preventive and predictive clinical laboratory services, is
pleased to announce the launch of a new genetic testing panel that detects
five genetic diseases specific to individuals of French Canadian origin.
PROCREA Cliniques becomes the first health center to offer the opportunity to
get tested for these five genetic diseases rapidly and in the same facility.
The reduced genetic diversity of the French Canadian population has
provided for severe debilitating and deadly genetic diseases to be common in
specific regions of Quebec such as tyrosinaemia, congenital lactic acidosis,
hereditary motor and sensory neuropathy, recessive spastic ataxia of
Charlevoix-Saguenay and cystic fibrosis.
Couples of French Canadian origin in the age of procreation, wanting to
know their genetic carrier status before having children, can now benefit from
these services. In the event of a positive test result Procrea Cliniques will
provide couples in need of support the personalized advice of a genetic
counselor to evaluate options and come up to an informed decision.
"The release of this panel of genetic tests further enhances the
commitment of our divison, Procrea Cliniques, to offer an evolving population,
integrated and complete, rapid and efficient, state-of-the-art diagnostic
services" said Dr. Pierre St-Michel CEO of Opmedic Group Inc.
About OPMEDIC GROUP
OPMEDIC GROUP is a company incorporated under the laws of the Province of
Quebec which provides healthcare-related services including surgical
facilities and services to patients and surgeons (with its OPMEDIC division),
fertility treatments, medical imaging, laboratory services and diagnostic
procedures (with its PROCREA Cliniques division) and sperm banking services
(with its PROCREA Cryopreservation Centre subsidiary). OPMEDIC GROUP's Common
Shares trade on the Toronto Stock Exchange under the symbol "OMG".
This news release does not constitute an offer to sell or to solicitation
of an offer to buy any security and shall not constitute an offer,
solicitation or sale in any jurisdiction in which such offering would be
unlawful. This news release contains certain forward-looking statements that
reflect the current views and/or expectations of OPMEDIC GROUP with respect to
its performance, business and future events. Such statements are subject to a
number of risks, uncertainties and assumptions. Actual results and events may
The Content of this press release has not been approved by nor submitted
to the TSX which assumes no liability therefore.
For further information:
For further information: Paulo Bouça, Vice President Business
Development and Chief Operating Officer, (514) 345-8535, x 2254,